- Previous Close
2.9700 - Open
2.9000 - Bid --
- Ask --
- Day's Range
2.6700 - 2.9000 - 52 Week Range
2.6700 - 4.8700 - Volume
9,273 - Avg. Volume
29,042 - Market Cap (intraday)
151.156M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6300 - Earnings Date May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.
www.inventivapharma.comRecent News: IVA
Performance Overview: IVA
Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVA
Valuation Measures
Market Cap
167.01M
Enterprise Value
178.28M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.13
Price/Book (mrq)
--
Enterprise Value/Revenue
9.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-69.19%
Return on Equity (ttm)
-1,642.75%
Revenue (ttm)
23.16M
Net Income Avi to Common (ttm)
-110.43M
Diluted EPS (ttm)
-2.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
27.34M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.88M